Management of Infections in Critically Ill Cancer Patients

  • Henry Masur
Part of the Current Clinical Oncology book series (CCO)


Advances in critical care medicine have enabled cancer patients to survive aggressive medical and surgical therapies that they could not have tolerated a decade ago. For patients whose goals can be met by ICU support, the diagnostic and empiric therapeutic approach will be far different than when patients are more stable in other hospital areas: evaluations must be completed rapidly while patients are able to tolerate such testing, and empiric therapy must be broad and promptly administered. Oncologists and infectious disease specialists need to be actively involved in evaluating cancer patients in the ICU and in developing their management plans due to the enhanced knowledge they are likely to have of the patient’s history prior to the ICU, their knowledge of the underlying disease and life-threatening process, and their expertise in drug selection and monitoring.


Critical Care ICU Infection 



Disclaimer: The opinions and assertions contained herein are those of the authors and are not to be construed as official or as reflecting the views of the Department of Defense, the Department of the Navy, or the naval services at large.

Disclaimer: The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Department of the Army or the U.S. Department of Defense.


  1. 1.
    Darmon M, Azoulay E. Critical care management of cancer patients: cause for optimism and need for objectivity. Curr Opin Oncol. 2009;21:318–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Azoulay E, Afessa B. The intensive care support of patients with malignancy: do everything that can be done. Intensive Care Med. 2006;32:3–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Soares M, Azoulay E. Critical care management of lung cancer patients to prolong life without prolonging dying. Intensive Care Med 2009.Google Scholar
  4. 4.
    Soares M. Salluh JI, Azoulay E. Noninvasive ventilation in patients with malignancies and hypoxemic acute respiratory failure: A still pending question. J Crit Care; 2009.Google Scholar
  5. 5.
    Pene F, Percheron S, Lemiale V, et al. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med. 2008;36:690–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Larche J, Azoulay E, Fieux F, et al. Improved survival of critically ill cancer patients with septic shock. Intensive Care Med. 2003;29:1688–95.CrossRefPubMedGoogle Scholar
  7. 7.
    Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med. 2003;31:104–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Lamia B, Hellot MF, Girault C, et al. Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU. Intensive Care Med. 2006;32:1560–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Park HY, Suh GY, Jeon K, et al. Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock. Leuk Lymphoma. 2008;49:1929–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Thakkar SG, Fu AZ, Sweetenham JW, et al. Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit. Cancer. 2008;112:2233–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Investigators TSP. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. Jama 1995;274:1591-8.Google Scholar
  12. 12.
    Angus DC, Barnato AE, Linde-Zwirble WT, et al. Use of intensive care at the end of life in the United States: an epidemiologic study. Crit Care Med. 2004;32:638–43.CrossRefPubMedGoogle Scholar
  13. 13.
    Curtis JR, Rubenfeld GD. Introducing the concept of managing death in the ICU. In: Curtis JR, Rubenfeld GD, eds. Managing death in the intensive care unit. New York: Oxford University Press; 2001:3.Google Scholar
  14. 14.
    Thiery G, Azoulay E, Darmon M, et al. Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol. 2005;23:4406–13.CrossRefPubMedGoogle Scholar
  15. 15.
    Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet. 2002;360:1131–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Ferra C, Marcos P, Misis M, et al. Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience. Int J Hematol. 2007;85:195–202.CrossRefPubMedGoogle Scholar
  17. 17.
    Massion PB, Dive AM, Doyen C, et al. Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med. 2002;30:2260–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Lecuyer L, Chevret S, Thiery G, Darmon M, Schlemmer B, Azoulay E. The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med. 2007;35:808–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Soubani AO, Kseibi E, Bander JJ, et al. Outcome and prognostic factors of hematopoietic stem cell transplantation recipients admitted to a medical ICU. Chest. 2004;126:1604–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Rabbat A, Chaoui D, Montani D, et al. Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol. 2005;129:350–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Merz TM, Schar P, Buhlmann M, Takala J, Rothen HU. Resource use and outcome in critically ill patients with hematological malignancy: a retrospective cohort study. Crit Care. 2008;12:R75.CrossRefPubMedGoogle Scholar
  22. 22.
    Benoit DD, Hoste EA, Depuydt PO, et al. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies. Nephrol Dial Transplant. 2005;20:552–8.CrossRefPubMedGoogle Scholar
  23. 23.
    den Boer S, de Keizer NF, de Jonge E. Performance of prognostic models in critically ill cancer patients - a review. Crit Care. 2005;9:R458–63.CrossRefGoogle Scholar
  24. 24.
    Beck DH, Smith GB, Pappachan JV, Millar B. External validation of the SAPS II, APACHE II and APACHE III prognostic models in South England: a multicentre study. Intensive Care Med. 2003;29:249–56.PubMedGoogle Scholar
  25. 25.
    Gondos A, Bray F, Hakulinen T, Brenner H. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol. 2009;20:564–73.CrossRefPubMedGoogle Scholar
  26. 26.
    Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.CrossRefPubMedGoogle Scholar
  27. 27.
    Miner JR, Heegaard W, Mapes A, Biros M. Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. J Emerg Med. 2001;21:387–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Proulx N, Frechette D, Toye B, Chan J, Kravcik S. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. Qjm. 2005;98:291–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Funk D, Sebat F, Kumar A. A systems approach to the early recognition and rapid administration of best practice therapy in sepsis and septic shock. Curr Opin Crit Care. 2009;15:301–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Marchaim D, Kaye KS, Fowler VG, et al. Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2009.Google Scholar
  31. 31.
    Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25–31.CrossRefPubMedGoogle Scholar
  32. 32.
    Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Critical Care Medicine Department, Clinical CenterNational Institutes of HealthBethesdaUSA

Personalised recommendations